drugset / Trial / NCT00375297

Study of Sildenafil for Treatment of SSRI-Antidepressant Sexual Dysfunction in Women

NCT00375297

Phase 4 Completed 100 enrolled University of New Mexico Pfizer · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

This prospective double-blind, placebo-controlled (DBPC) study, assessed the efficacy of sildenafil in women with serotonin reuptake inhibitor antidepressant-associated sexual dysfunction (SRI-AASD) following the same protocol which previously established efficacy in men with SRI-AASD.

Timeline

Start
2001-01
Primary completion
Completion
2005-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Sildenafil Unknown 50 mg
Subject Sildenafil Unknown 100 mg